Table 1 Demographics of amyloid-negative participants
From: Age, vascular disease, and Alzheimer’s disease pathologies in amyloid negative elderly adults
Diagnosis | Cognitively unimpaired (CU) | Cognitively impaired (CI) |
|---|---|---|
Sample size | 149 | 52 |
Age (median (IQR)) | 69.3(7.1) | 71.8(16.8) |
Education (median (IQR)) | 18 (2) | 16 (5) |
Females (no., %) | 95 (63.8%)a | 20 (38.5%) |
APOE4 (no., %) | 33 (22.1%) | 5 (9.6%) |
BMI (median (IQR)) | 26.7 (6.4) | 27.6 (5.0) |
Smoking history (no., %) | 5 (3.4%) | 5 (9.6%) |
Diabetes (no., %) | 18 (12.1%) | 5 (9.6%) |
Hyperlipidemia (no., %) | 67 (45.0%) | 25 (48.1%) |
Hypertension (no., %) | 54 (36.2%) | 33 (63.5%)b |
CSF Aβ42/Aβ40 (median (IQR)) | 0.086 (0.020) | 0.088 (0.014) |
Aβ PET centiloid (median (IQR)) | 4.09 (10.21) | 4.02 (14.93) |
CSF p-Tau/Aβ40 (median (IQR)) | 0.0009 (0.0002) | 0.0010 (0.0002) c |
WMH (median (IQR)) | −2.96 (0.67) | −2.87 (0.71) d |
PACC (median (IQR)) | 1.09 (3.61) | −4.65 (4.59) e |
81 participants with aHCV and FDG | ||
Sample size | 32 | 49 |
aHCV (mm3) (median (IQR)) | 7723 (1064) | 7319 (2683) f |
FDG SUVR (median (IQR)) | 1.32 (0.09) | 1.29 (0.15) g |